DK2017251T3 - Fremgangsmåde til stabilisering af reduceret coenzym Q10 - Google Patents

Fremgangsmåde til stabilisering af reduceret coenzym Q10 Download PDF

Info

Publication number
DK2017251T3
DK2017251T3 DK07742687.2T DK07742687T DK2017251T3 DK 2017251 T3 DK2017251 T3 DK 2017251T3 DK 07742687 T DK07742687 T DK 07742687T DK 2017251 T3 DK2017251 T3 DK 2017251T3
Authority
DK
Denmark
Prior art keywords
reduced coenzyme
coenzyme
reduced
oxidized
composition
Prior art date
Application number
DK07742687.2T
Other languages
English (en)
Inventor
Takahiro Ueda
Shiro Kitamura
Kazunori Hosoe
Hiroshi Kubo
Original Assignee
Kaneka Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38655603&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2017251(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kaneka Corp filed Critical Kaneka Corp
Application granted granted Critical
Publication of DK2017251T3 publication Critical patent/DK2017251T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C41/00—Preparation of ethers; Preparation of compounds having groups, groups or groups
    • C07C41/01—Preparation of ethers
    • C07C41/34—Separation; Purification; Stabilisation; Use of additives
    • C07C41/46—Use of additives, e.g. for stabilisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/35—Ketones, e.g. benzophenone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Birds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Fodder In General (AREA)
  • Cosmetics (AREA)

Claims (12)

1. Fremgangsmåde til stabilisering af reduceret coenzym Qio, hvilken fremgangsmåde omfatter at opnå samtidig tilstedeværelse af det reducerede coenzym Qio og følgende (a) og/eller (b): (a) ikke under 1,5 % efter vægt til ikke over 99 % efter vægt reduceret coenzym Qg i forhold til det reducerede coenzym Qio, og/eller (b) reduceret coenzym Qn.
2. Fremgangsmåde ifølge krav 1, hvor førnævnte (a) reduceret coenzym Qg og (b) reduceret coenzym Qu fremstilles og tilsættes hver for sig.
3. Fremgangsmåde ifølge krav 1, hvor den samtidige tilstedeværelse opnås ved at reducere det oxiderede coenzym Qio omfattende oxideret coenzym Qg og/eller oxideret coenzym Qu.
4. Fremgangsmåde ifølge et hvilket som helst af kravene 1 til 3, hvor den samtidige tilstedeværelse opnås i en deoxygeneringsatmosfære.
5. Reduceret coenzym Qio-holdig sammensætning omfattende følgende (a) og/eller (b) i kombination med det reducerede coenzym Qi0: (a) ikke under 1,5 % efter vægt til ikke over 99 % efter vægt reduceret coenzym Qg i forhold til det reducerede coenzym Qio, og/eller (b) reduceret coenzym Qu.
6. Sammensætning ifølge krav 5, hvor det reducerede coenzym Qio er en krystal.
7. Sammensætning ifølge krav 5, hvor det reducerede coenzym Qio er opløst eller opslæmmet i et opløsningsmiddel.
8. Sammensætning ifølge krav 5, hvor det reducerede coenzym Qio er en smelte.
9. Sammensætning ifølge krav 5, som er i en form, der kan indgives til et pattedyr og omfatter reduceret coenzym Qio som en virksom bestanddel.
10. Sammensætning ifølge krav 5, omfattende mindst et medlem af gruppen bestående af en excipiens, et desintegrationsmiddel, et smøremiddel, et bindemiddel, en antioxidant, et farvestof, et antikoagulationsmiddel, et absorptionsfremmende middel, et middel, der fremmer opløseligheden af den virksomme bestanddel, en stabilisator og en anden virksom bestanddel end det reducerede coenzym Qio.
11. Sammensætning ifølge krav 10, som er en kapsel.
12. Fremgangsmåde til fremstilling af sammensætning indeholdende reduceret coenzym Qio, hvilken sammensætning omfatter følgende (a) og/eller (b) i kombination med det reducerede coenzym Qi0: (a) ikke under 1,5 % efter vægt til ikke over 99 % efter vægt reduceret coenzym Qg i forhold til det reducerede coenzym Qio, og/eller (b) reduceret coenzym Qu, hvilken fremgangsmåde omfatter (i) at fremstille og tilsætte (a) og/eller (b) hver for sig, eller ΓϋΊ at reducere oxideret rnenzvm Dm indeholdende oxideret coenzvm Du on/eller oxideret coenzym Q9, hvor det oxiderede coenzym Q9 er til stede med ikke mindre end 0,6 % efter vægt i forhold til oxideret coenzym Qio.
DK07742687.2T 2006-04-28 2007-04-27 Fremgangsmåde til stabilisering af reduceret coenzym Q10 DK2017251T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006126897 2006-04-28
PCT/JP2007/059252 WO2007126083A1 (ja) 2006-04-28 2007-04-27 還元型補酵素ｑ10の安定化方法

Publications (1)

Publication Number Publication Date
DK2017251T3 true DK2017251T3 (da) 2017-09-18

Family

ID=38655603

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07742687.2T DK2017251T3 (da) 2006-04-28 2007-04-27 Fremgangsmåde til stabilisering af reduceret coenzym Q10

Country Status (12)

Country Link
US (1) US7829080B2 (da)
EP (2) EP2017251B1 (da)
JP (1) JP5286081B2 (da)
KR (1) KR101376344B1 (da)
CN (1) CN101432256B (da)
AU (1) AU2007244232B2 (da)
CA (1) CA2650686C (da)
DK (1) DK2017251T3 (da)
ES (1) ES2639567T3 (da)
PL (1) PL2017251T3 (da)
TW (1) TW200808344A (da)
WO (1) WO2007126083A1 (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2410587T3 (es) 2004-01-22 2013-07-02 University Of Miami Formulaciones tópicas de coenzima Q10 y métodos de uso
US20070053985A1 (en) * 2005-08-24 2007-03-08 Kaneka Corporation Coenzyme Q10-containing fine particle with excellent dispersibility
MX337408B (es) 2007-03-22 2016-03-03 Berg Llc Formulaciones topicas que tienen biodisponibilidad aumentada.
WO2009126764A1 (en) 2008-04-11 2009-10-15 Cytotech Labs, Llc Methods and use of inducing apoptosis in cancer cells
EA023913B1 (ru) 2009-05-11 2016-07-29 БЕРГ ФАРМА ЭлЭлСи Способы лечения метаболических нарушений, использующие эпиметаболические переключатели, многоаспектные внутриклеточные молекулы или факторы влияния
EP2489652B1 (en) * 2009-10-16 2018-07-25 Kaneka Corporation Method for producing reduced coenzyme q10, method for stabilizing same, and composition comprising same
KR101907411B1 (ko) 2010-03-12 2018-10-12 베르그 엘엘씨 코엔자임 Ｑ10(ＣｏＱ10)의 정맥내 제형 및 이의 사용 방법
WO2011132718A1 (ja) * 2010-04-20 2011-10-27 株式会社カネカ 還元型補酵素ｑ１０含有組成物とその製造方法及び安定化方法
CN101966171B (zh) * 2010-09-30 2012-10-24 杭州华东医药集团康润制药有限公司 水溶性还原型辅酶q10组合物及其制备方法
CN103608323B (zh) 2011-04-04 2016-08-17 博格有限责任公司 治疗中枢神经系统肿瘤的方法
CN107095863A (zh) 2011-06-17 2017-08-29 博格有限责任公司 可吸入药物组合物
RU2509760C2 (ru) * 2011-07-11 2014-03-20 Закрытое акционерное общество "Научно-производственное объединение "ДОМ ФАРМАЦИИ" ВОДОРАСТВОРИМЫЙ МОЛЕКУЛЯРНЫЙ КОМПЛЕКС ВКЛЮЧЕНИЯ ВОССТАНОВЛЕННОЙ ФОРМЫ КОЭНЗИМА Q10 В β-ЦИКЛОДЕКСТРИНЕ И СПОСОБ ЕГО ПРЕПАРАТИВНОГО ПОЛУЧЕНИЯ
EP2983654B1 (en) 2013-04-08 2025-11-12 BPGbio, Inc. Treatment of cancer using coenzyme q10 combination therapies
CN103211217A (zh) * 2013-04-25 2013-07-24 福建永生活力生物工程有限公司 一种增强免疫力功能的保健软胶囊及其制备方法
WO2015035094A1 (en) 2013-09-04 2015-03-12 Berg Llc Methods of treatment of cancer by continuous infusion of coenzyme q10
US20170189350A1 (en) 2015-11-16 2017-07-06 Berg Llc Methods of treatment of temozolomide-resistant glioma using coenzyme q10
US11471426B2 (en) 2019-10-16 2022-10-18 American River Nutrition, Llc Compositions comprising quinone and/or quinol and methods of preparations and use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5577895A (en) * 1978-12-07 1980-06-12 Nisshin Flour Milling Co Ltd Preparation of coenzyme q11
JP3889481B2 (ja) 1996-08-16 2007-03-07 株式会社カネカ 医薬組成物
US6878514B1 (en) * 1999-03-30 2005-04-12 Purdue Research Foundation Methods for identifying agents that inhibit serum aging factors and uses and compositions thereof
US8753675B1 (en) 2000-01-20 2014-06-17 Raj K. Chopra Reduced form of Coenzyme Q in high bioavailability stable dosage forms and related applications
TWI310029B (da) 2001-07-13 2009-05-21 Kaneka Corp
TWI237018B (en) 2001-07-13 2005-08-01 Kaneka Corp Method of producing reduced coenzyme Q10 crystals
TWI329510B (en) * 2001-10-10 2010-09-01 Kaneka Corp Method of stabilizing reduced coenzyme q10
JP2006126897A (ja) 2004-10-26 2006-05-18 Matsushita Electric Works Ltd 煙感知器用試験器

Also Published As

Publication number Publication date
US7829080B2 (en) 2010-11-09
TW200808344A (en) 2008-02-16
CA2650686A1 (en) 2007-11-08
AU2007244232B2 (en) 2012-07-19
KR101376344B1 (ko) 2014-03-20
EP3279180A1 (en) 2018-02-07
US20070258966A1 (en) 2007-11-08
CN101432256B (zh) 2012-11-28
ES2639567T3 (es) 2017-10-27
AU2007244232A1 (en) 2007-11-08
CA2650686C (en) 2014-12-16
CN101432256A (zh) 2009-05-13
EP2017251B1 (en) 2017-07-19
PL2017251T3 (pl) 2017-12-29
EP2017251A4 (en) 2013-01-09
WO2007126083A1 (ja) 2007-11-08
EP2017251A1 (en) 2009-01-21
JP5286081B2 (ja) 2013-09-11
JPWO2007126083A1 (ja) 2009-09-10
KR20090017547A (ko) 2009-02-18

Similar Documents

Publication Publication Date Title
AU2007244232B2 (en) Method for stabilization of reduced coenzyme Q10
CA2462557C (en) Method of stabilizing reduced coenzyme q10
US20070258967A1 (en) Purification method of reduced coenzyme q10
JP5364580B2 (ja) 還元型補酵素ｑ１０の製造方法、ならびに、その安定化方法
JP5810079B2 (ja) 還元型補酵素ｑ１０含有組成物とその製造方法及び安定化方法
JP4855551B2 (ja) 還元型補酵素ｑ１０の製造方法、安定化方法及びそれを含有する組成物
JP5546935B2 (ja) 還元型補酵素ｑ１０含有組成物及びその製法方法
JP4786000B2 (ja) 還元型補酵素ｑ１０の製造方法、安定化方法及びそれを含有する組成物